Peptide Monographs

BPC-157 and Thymosin beta 4 side by side

BPC-157 and Thymosin beta 4 are both indexed under Tissue repair peptides. Every cell below carries the record it came from, and an axis with no retrieved value reads Unknown rather than being filled by inference.

Summary

Both sit in the tissue repair grouping, which is defined by research endpoint rather than by a shared receptor, and their mechanisms in the retrieved literature are unrelated. BPC-157 is framed in terms of a relation to the nitric oxide system; thymosin beta 4 is identified as an actin-sequestering peptide.

[1, 2, 3, 4]

Side by side

Curated comparison axes for BPC-157 and Thymosin beta 4
AxisBPC-157Thymosin beta 4
Reported mechanismThe retrieved literature frames the mechanism in terms of a relation to the nitric oxide system, and reports effects on growth hormone receptor expression in tendon fibroblasts. No single receptor target is established in the retrieved record set.[1, 10]Actin sequestration; identified in the retrieved literature as an actin-sequestering peptide that participates in the control of actin filament dynamics.[2, 3]
Molecular formulaC62H98N16O22[5]C212H350N56O78S[12]
Molecular weight1419.5 g/mol[5]4963 g/mol[12]
FDA application registerA query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[6]A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[13]

Where the two literatures diverge

Mechanism diverges completely, which is the point of the pair: the cited 2014 Current Pharmaceutical Design paper frames BPC-157 against the nitric oxide system, while the cited 1991 Journal of Biological Chemistry and 1992 Molecular Biology of the Cell papers place thymosin beta 4 in actin filament dynamics. Origin diverges: thymosin beta 4 is a naturally occurring peptide whose complete bovine amino acid sequence was reported in 1981, while the BPC-157 literature begins with synthetic fragment work in 1994. Molecular weight diverges by roughly a factor of three on the retrieved PubChem records. Neither returned an FDA application record.

[1, 2, 3, 4]

Where this page sits

Full pages: BPC-157 and Thymosin beta 4.

Shared class: Tissue repair peptides.

Other pairs in the same class

All side-by-side pages: index.

Sources

  1. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des (2014). pmid:23755725
  2. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem (1991). pmid:1999398
  3. The control of actin nucleotide exchange by thymosin beta 4 and profilin. A potential regulatory mechanism for actin polymerization in cells. Mol Biol Cell (1992). pmid:1330091
  4. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A (1981). pmid:6940133
  5. PubChem Compound Summary for CID 9941957, Bpc-157. PubChem, National Library of Medicine (2026). pubchem:9941957
  6. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:bpc-157
  7. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life Sci (1994). pmid:7904712
  8. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol (1997). pmid:9298922
  9. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985) (2011). pmid:21030672
  10. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). pmid:25415472
  11. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol (2007). pmid:17628536
  12. PubChem Compound Summary for CID 45382195, Thymosin Beta 4. PubChem, National Library of Medicine (2026). pubchem:45382195
  13. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:thymosin-beta-4
  14. How profilin promotes actin filament assembly in the presence of thymosin beta 4. Cell (1993). pmid:8252614
  15. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J (1997). pmid:9194528

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Related resources